Focus On Cancer

Guest: John Docherty Host: Bruce Japsen Cancer cells can be made to become more vulnerable to treatments like chemotherapy, and there are therapeutics under development which are designed to impact this so-called microenvironment of tumor cells. John Docherty, president of Toronto-based Helix BioPharma, tells host Bruce Japsen about a new wave of treatments and therapies in the biotechnology industry that could better target cancer cells and in turn help patients deal with the side effects of chemotherapy.